- Stocks
- Pharma & Healthcare
- Godavari Drugs
Godavari Drugs share price
NSE: GODAVARIPharma & HealthcareDrug Manufacturers - Specialty & Generic
Godavari Drugs at a glance
With a market capitalisation of ₹120 Cr, it ranks 2567th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 10.1% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹33 Cr (+30.0% year on year) and net profit ₹1 Cr (+44.9%), on a standalone basis. Promoters held 40.23% of the company as of 30 Jun 2026; 0.21% of promoter shares were pledged.
Key numbers
- Market cap
- ₹120 CrRank 2567 on NSE
- Price to book
- 1.52×FY25
- EPS (TTM)
- ₹5.43to Q4 FY26
- ROE
- 10.1%FY25
- ROCE
- 14.8%FY25
- Debt to equity
- 1.42FY25
- Net profit margin
- 3.9%FY25
- Book value / share
- ₹57.56FY25
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Godavari Drugs quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹32 Cr | ₹26 Cr | ₹30 Cr | ₹26 Cr | ₹24 Cr | ₹27 Cr | ₹22 Cr | ₹33 Cr |
| Revenue YoY | −9.1% | −34.0% | −31.5% | −34.0% | −26.1% | +2.1% | −24.9% | +30.0% |
| Net profit | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Net profit YoY | +101.2% | +26.7% | −36.9% | −66.5% | −36.2% | −8.3% | −1.3% | +44.9% |
| Net margin | 5.1% | 4.2% | 2.6% | 3.5% | 4.4% | 3.8% | 3.4% | 3.9% |
| EPS | ₹2.17 | ₹1.45 | ₹1.02 | ₹1.19 | ₹1.38 | ₹1.33 | ₹1.01 | ₹1.71 |
Godavari Drugs financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹96 Cr | ₹123 Cr | ₹161 Cr | ₹160 Cr | ₹157 Cr | ₹113 Cr |
| Operating profit | ₹2 Cr | ₹6 Cr | ₹7 Cr | ₹5 Cr | ₹7 Cr | ₹6 Cr |
| Net profit | ₹2 Cr | ₹4 Cr | ₹5 Cr | ₹4 Cr | ₹6 Cr | ₹4 Cr |
| EPS (₹) | ₹2.66 | ₹5.48 | ₹6.97 | ₹5.03 | ₹7.37 | ₹5.82 |
| Cash from operations | ₹6 Cr | ₹1 Cr | ₹11 Cr | ₹13 Cr | ₹18 Cr | ₹11 Cr |
| Total debt | ₹11 Cr | ₹14 Cr | ₹12 Cr | ₹12 Cr | ₹11 Cr | ₹24 Cr |
| Shareholders' equity | ₹20 Cr | ₹24 Cr | ₹30 Cr | ₹33 Cr | ₹39 Cr | ₹43 Cr |
Godavari Drugs shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 18 Mar 2026 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 52.63% | 52.61% | 52.61% | 40.23% | 40.23% | 40.23% |
| Domestic institutions | 0.50% | 0.50% | 0.50% | 2.47% | 2.47% | 2.74% |
| Non-institutions | 46.87% | 46.89% | 46.89% | 57.30% | 57.30% | 57.03% |
| Promoter shares pledged | 0.25% | 0.22% | 0.22% | 0.21% | 0.21% | 0.21% |
Godavari Drugs vs peers
The listed Pharma & Healthcare companies nearest to Godavari Drugs by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ASPIRAAspira Pathlab | — | — | — | ₹125 Cr | — | — |
| PARNAXLABParnax Lab | ₹108.95 | −3.52% | — | ₹125 Cr | 10.6 | — |
| KREBSBIOKrebs Biochemicals and Industries | ₹57.16 | −5.99% | −20.6% | ₹123 Cr | — | — |
| MAKERSLMakers Labs | ₹209.00 | +0.05% | — | ₹123 Cr | 52.5 | — |
| GODAVARIGodavari Drugs | — | — | — | ₹120 Cr | — | — |
| BALAXIBALAXI PHARMACEUTICALS | ₹21.72 | −2.12% | −50.2% | ₹120 Cr | 83.5 | — |
| PHARMAIDPharmaids Pharm | — | — | — | ₹113 Cr | — | — |
Ask anything about Godavari Drugs
Pivot answers on the live chart with evidence you can check, and tests strategies against GODAVARI's own history. Try: “Why has GODAVARI moved over the last three months?” · “Backtest a 50-day moving-average crossover on GODAVARI over five years” · “Compare GODAVARI with ASPIRA on margins and valuation”
Frequently asked questions about Godavari Drugs
What is the market cap of Godavari Drugs?
Godavari Drugs' market capitalisation is ₹120 Cr (₹120 Cr) at the 19 Oct 2026 close, ranking 2567th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Godavari Drugs?
Return on equity was 10.1% in FY25 and return on capital employed was 14.8% in FY25 (standalone figures).
Is Godavari Drugs a debt-free company?
No. Godavari Drugs' debt-to-equity ratio was 1.42 in FY25, with total debt of ₹24 Cr.
What were Godavari Drugs' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Godavari Drugs reported revenue of ₹33 Cr, +30.0% year on year, and net profit of ₹1 Cr, +44.9% year on year.
What is the shareholding pattern of Godavari Drugs?
As of 30 Jun 2026: promoters 40.23%, domestic institutions 2.74%, non-institutions 57.03%. 0.21% of promoter shares were pledged.
Who are Godavari Drugs' competitors?
The listed Pharma & Healthcare companies closest to Godavari Drugs by market cap are Aspira Pathlab, Parnax Lab, Krebs Biochemicals and Industries, Makers Labs, BALAXI PHARMACEUTICALS and Pharmaids Pharm.
Is Godavari Drugs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Godavari Drugs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GODAVARI against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with G · all NSE stocks · this page as text